Efficacy of pimavanserin for patients with psychosis in Parkinson's disease: A systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v13i1.44895

Keywords:

Parkinson's disease; Psychotic disorders; Antipsychotic agents.

Abstract

The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice.

References

Artigos - Neuropulse. (n.d.). Www.neuropulse.com.br. https://www.neuropulse.com.br/artigos/alteracoes-de-memoria-na-doenca-de-parkinson/.

Ballard, C., Isaacson, S., Mills, R., Williams, H., Corbett, A., Coate, B., ... & Burn, D. J. (2015). Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. Journal of the American Medical Directors Association, 16(10), 898-e1.

Ballard, C., Banister, C., Khan, Z., Cummings, J., Demos, G., Coate, B., Youakim, J. M., Owen, R., Stankovic, S., Tomkinson, E. B., McDermid, J., Ocal, D., Testad, I., Qayyum, M. A., Kemos’, P., Borejko, O., Megalogeni, M., Brookes, E. V., Petrava, A., & Da Silva, M. (2018). Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet Neurology, 17(3), 213–222. https://doi.org/10.1016/s1474-4422(18)30039-5.

Binde, C. D., Tvete, I. F., Gåsemyr, J. I., Natvig, B., & Klemp, M. (2020). Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-020-02961-6.

Borges, R., & Kauark, G. (n.d.). Retrieved November 15, 2023, from https://repositorio.unifesp.br/xmlui/bitstream/handle/11600/50032/Roberta%20Borges%20Gomes%20Kauark%20PDF%20A.pdf?sequence=1&isAllowed=y.

Bruno Fukelmann Guedes, Gonçalves, M., & Rubens Gisbert Cury. (2016). Psychosis and concurrent impulse control disorder in Parkinson’s disease: A review based on a case report. Dementia & Neuropsychologia, 10(2), 148–151. https://doi.org/10.1590/s1980-5764-2016dn1002011.

Citrome, L., Norton, J. C., Chi-Burris, K., & Demos, G. (2018). Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums, 23(3), 228–238. 10.1017/s1092852917000736.

Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (London, England), 383(9916), 533–540. https://doi.org/10.1016/S0140-6736(13)62106-6.

Darwish, M., Bugarski-Kirola, D., Passarell, J., Owen, J., Jaworowicz, D., DeKarske, D., & Stankovic, S. (2022). Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study. Journal of Clinical Psychopharmacology, 42(6), 544–551. https://doi.org/10.1097/JCP.0000000000001611.

Dirks, B., Fava, M., Atkinson, S. D., Joyce, M., Thase, M. E., Howell, B., Lin, T., & Stankovic, S. (2022). Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies. Psychopharmacology Bulletin, 52(4), 8–30. https://pubmed.ncbi.nlm.nih.gov/36339271/.

Espay, A. J., Guskey, M. T., Norton, J. C., Coate, B., Vizcarra, J. A., Ballard, C., … Weintraub, D. (2018). Pimavanserin for Parkinson’s Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications. Movement Disorders: Official Journal of the Movement Disorder Society, 33(11), 1769–1776. 10.1002/mds.27488.

Estrela, C. (2018). Metodologia científica: ciência, ensino, pesquisa. Artes Médicas.

Iketani, R., Furushima, D., Imai, S., & Yamada, H. (2020). Efficacy and safety of atypical antipsychotics for psychosis in Parkinson’s disease: A systematic review and Bayesian network meta-analysis. Parkinsonism & Related Disorders, 78, 82–90. 10.1016/j.parkreldis.2020.07.021.

Isaacson, S. H., Coate, B., Norton, J., & Stankovic, S. (2020). Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis. Journal of Parkinson’s Disease, 10(4), 1389–1396. https://doi.org/10.3233/jpd-202047.

Isaacson, S. H., Ballard, C. G., Kreitzman, D. L., Coate, B., Norton, J. C., Fernandez, H. H., Ilic, T. V., Azulay, J.-P., Ferreira, J. J., Abler, V., & Stankovic, S. (2021). Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism & Related Disorders, 87, 25–31. https://doi.org/10.1016/j.parkreldis.2021.04.012.

Jethwa, K. D., & Onalaja, O. A. (2015). Antipsychotics for the management of psychosis in Parkinson’s disease: systematic review and meta-analysis. BJPsych Open, 1(1), 27–33. https://doi.org/10.1192/bjpo.bp.115.000927.

Orgeta, V., McDonald, K. R., Poliakoff, E., Hindle, J. V., Clare, L., & Leroi, I. (2020). Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011961.pub2.

Pamplona, L. de A. e L., & Mattos, J. P. de. (1996). Demência na doença de Parkinson: avaliação crítica da literatura. Arquivos de Neuro-Psiquiatria, 54(4), 687–690. https://doi.org/10.1590/s0004-282x1996000400023.

Salvador. (2022). Curso de medicina henrique nascimento dourado a prevalência de psicose na doença de Parkinson. http://www.repositorio.bahiana.edu.br/jspui/bitstream/bahiana/7112/1/Henrique%20Nascimento%20Dourado%20-%20A%20preval%c3%aancia%20de%20psicose%20na%20doen%c3%a7a%20de%20parkinson%20-%202022.pdf.

Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., Stankovic, S., & Foff, E. P. (2021). Trial of Pimavanserin in Dementia-Related Psychosis. The New England journal of medicine, 385(4), 309–319. https://doi.org/10.1177/0891988716640378.

Published

30/01/2024

How to Cite

MENDES, R. da C. .; SOUZA, S. P. .; SILVA JUNIOR, L. C. A. da .; CARVALHO, J. S. de .; COELHO , V. H. O. M. .; HORTA, W. G. . Efficacy of pimavanserin for patients with psychosis in Parkinson’s disease: A systematic review. Research, Society and Development, [S. l.], v. 13, n. 1, p. e13713144895, 2024. DOI: 10.33448/rsd-v13i1.44895. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/44895. Acesso em: 20 may. 2024.

Issue

Section

Health Sciences